Grant: Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)
University of British Columbia
$99,715.00
Designing a novel vaccine against herpes simplex virus 2
EF 2023-24
Résumé
Herpes simplex virus 2 (HSV-2) is a sexually transmitted virus that affects over 500 million individuals worldwide. HSV-2 establishes a life-long infection with the host and causes lesions, pain, and discomfort in the female genital tract that persists for life. In addition, HSV-2 infection increases the risk of co-infection by HIV or hepatitis C virus as well as pathogenic bacteria that are responsible for bacterial vaginosis. Although the antiviral drug, acyclovir, is available, acyclovir needs to be taken as a daily five dose regimen for the duration of
symptoms and does not prevent recurring symptoms. There are currently no vaccines available to treat HSV-2, in part due to inherent challenges associated with the development of mucosal vaccines. The goal of our project is to design a new vaccine against HSV-2 by combining the advantages of several existing vaccine platforms. We will test the efficacy in mouse models of vaginal HSV-2 infection. As no successful vaccines are available for HSV-2, our work has the potential to ignite new avenues of research in the development of vaccines against HSV-2.
Programme
Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
488762
Name
Tokuyama Maria
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
STBBI Research in Canada: Beyond HIV/AIDS and Hepatitis C (Catalyst)
Projecttitle
Designing a novel vaccine against herpes simplex virus 2
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$99,715
Cihrequipment2
$0
Programname2
Cat. Gr.: STBBI Res.: Beyond HIV/AIDS/Hep. C- STBBI other than HIV/hep. C (gen.)
Keyworddelim
Antiviral Immunity; Endogenous Retroviruses; Epithelial Repair; Female Genital Tract; Mucosal Barrier Integrity; Sexually Transmitted Infections; Vaginal Epithelium
Abstract
Herpes simplex virus 2 (HSV-2) is a sexually transmitted virus that affects over 500 million individuals worldwide. HSV-2 establishes a life-long infection with the host and causes lesions, pain, and discomfort in the female genital tract that persists for life. In addition, HSV-2 infection increases the risk of co-infection by HIV or hepatitis C virus as well as pathogenic bacteria that are responsible for bacterial vaginosis. Although the antiviral drug, acyclovir, is available, acyclovir needs to be taken as a daily five dose regimen for the duration of
symptoms and does not prevent recurring symptoms. There are currently no vaccines available to treat HSV-2, in part due to inherent challenges associated with the development of mucosal vaccines. The goal of our project is to design a new vaccine against HSV-2 by combining the advantages of several existing vaccine platforms. We will test the efficacy in mouse models of vaginal HSV-2 infection. As no successful vaccines are available for HSV-2, our work has the potential to ignite new avenues of research in the development of vaccines against HSV-2.
Competitiondate
202305
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tokuyama, Maria
Approvedterm
1 an 0 mois
Cihrcontribution2
MI #3~ $99,715~ $0~